Aspreva Pharmaceuticals Corporation is currently working to provide more evidence-based φάρμακα for less common diseases. The company recently announced the initiation of a Phase III trial to evaluate the safety and efficacy of CellCept (mycophenolate mofetil) with corticosteroids to achieve remission in patients with pemphigus vulgaris. The randomized double-blind, placebo-controlled trial will evaluate mycophenolate mofetil in 77 patients with active pemphigus vulgaris over 52 weeks. The primary endpoint of this study is defined as minimally active disease (no persistent or new lesions) with CellCept and low-dose Στεροειδών. The study will be completed in 2007.
Το Peptimmune ξεκινά τη δοκιμή Φάσης Ι για περονόσπορο vulgaris.
Γνωρίστε δερματικά σημάδια εσωτερικών κακοηθειών.
Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation.
The authors present three patients with severe GVHD not responding to treatment with steroids. The cohort of patients had developed grade II-IV GVHD after transplant and received treatment with high-dose steroids for a median of 7 days (range 7-10) in ……
Sponsors and Collaborators: Aspreva Pharmaceuticals, as part of the Roche-Aspreva Collaboration Agreement. Pemphigus vulgaris (PV) is a rare, severe, and chronic autoimmune disease that causes blisters of the skin and mucous membranes. This study will test the safety and efficacy ……